A Regional Hub for High-Impact Vaccine Trials and Global Health Partnerships
VCRC is the specialized research arm of the Holding Company for Biological Products and Vaccines (VACSERA), the oldest producer of vaccines in the Middle East. Established in 2001 with a skilled and experienced team, capable of conducting clinical studies while maintaining full compliance with regulatory and quality standards, bridging the gap between advanced vaccine manufacturing and public health impact.
Enabling High-Impact Clinical Research in Egypt & the Region
VCRC's Key Strategic Objective is to enable high-impact clinical research in Egypt by streamlining drug development, improving patient access to advanced care, developing regional research capacity for multinational trials, and integrating key stakeholders into a unified national clinical trials ecosystem.
Support high quality, evidence-generating, research activities at VACSERA
Enhance the body of knowledge on clinical research in and outside VACSERA
Support the development and sustainability of the clinical research industry in Egypt
Establishing a Regional Clinical Excellence Hub for Vaccine Validation & Phase IV Surveillance
Serving North Africa and driving continental health security in alignment with Africa CDC's 2040 vision.
Accelerate Vaccine Access
Host clinical trials for priority pipeline and accelerate regulatory registration.
Regional Hub Development
Serve as a training and validation center for North Africa to support Africa CDC’s 2040 vision.
Post-Marketing Excellence
Lead Phase IV studies to ensure long-term vaccine safety and efficacy across diverse African populations.
Physical Infrastructure of CRC
Located downtown at Giza in Dokki district so it is easily accessible to the target population intended to be recruited for clinical trials, fully equipped with comprehensive diagnostic and patient care systems.
VCRC Clinical Examination & Monitoring Units
Compliant with International GCP Guidelines
Qualified Healthcare Professionals & Lead Investigators
VACSERA has got qualified healthcare professionals including: Operational, Regulatory & Quality site management team, along with Physicians, Nurses, and Research staff.
Lead Investigators Therapeutic Expertise
- Vaccines
- Allergy & Immunology
- Diabetes
- Blood Diseases (Hematology)
- Cardiology
“Maintaining a 100% GCP compliance rate and are supported by a robust recruitment infrastructure that consistently delivers high-quality data and meets enrolment milestones ahead of schedule.”
— VCRC Quality & Clinical Operations
Comprehensive Suite of Services for Global Vaccine Developers
We offer a comprehensive suite of services for international vaccine developers and global health organizations.
Full-Scale Clinical Trial Management
Expertise in Phase III and Phase IV interventional clinical trials.
Mega-Trial Execution
Proven capacity to recruit hundreds of participants simultaneously with high retention rates.
Regulatory & Ethical Navigation
Streamlined processes for National Regulatory Authority (EDA) approvals, Supreme Council, and Ethics Committee (IRB) submissions.
Capacity Building Programs
For enhancing clinical research and drug development capabilities in Egypt.
Patient Recruitment & Retention
Targeted patient access backed by VACSERA's extensive healthcare network across Egypt.
Pharmacovigilance & Safety Reporting
Continuous safety monitoring and adverse event reporting compliant with international standards.
Bioequivalence (BE) Services
End-to-end bioequivalence study protocols, crossover designs, and clinical execution.
Phase III • Phase IV • Interventional Clinical Trials
Robust Infrastructure & Extensive Patient Populations
Comprehensive capabilities supporting recruitment, cold chain management, and clinical care across Egypt.
VACSERA Vaccination Centers Network
Central center located in Dokki, Giza, connected to a nationwide network of over 28 vaccination centers across 7 governorates for seamless trial participant recruitment.
Blood Issuing Center & Transfusion Services
Central blood transfusion hub receiving more than 16,000 patients annually, providing biological fluids and hematological access for specialized clinical trials.
VACSERA Kidney Center
Dedicated nephrology and dialysis facility equipped with advanced renal care infrastructure, facilitating specialized clinical and biological investigations.
VACSERA Diabetes Center
High-volume specialized clinic receiving approximately 6,000 diabetic patients annually, offering extensive patient populations for endocrinology and metabolic studies.
VACSERA Medical Center Polyclinics
Comprehensive multidisciplinary clinics spanning Diabetes, Cardiology, Orthopedics, Pediatrics, Ophthalmology, Dentistry, and Gynecology.
VACSERA National Heart Center
A state-of-the-art cardiovascular facility dedicated to delivering advanced cardiac care, equipped with modern cardiac catheterization labs, ICU, and inpatient beds.
Allergy and Immunology Center
Specialized clinical and diagnostic hub for immunological assessments, allergy testing, and immunotherapy research protocols.
VACSERA Depot & Central Cold Storage
Fully qualified, validated pharmaceutical storage and distribution facility designed to strictly comply with international GSP and GDP guidelines. Accredited temperature-controlled chambers with 24/7 continuous monitoring systems.
Dedicated Incineration Unit
Dedicated, high-efficiency incineration unit serving as the certified final step for the safe disposal of hazardous, cytotoxic, and high-risk clinical research waste.
Two WHO Regional Reference Laboratories
VACSERA proudly hosts two World Health Organization Regional Reference Laboratories: (1) WHO Regional Reference Laboratory for Polio (RRL) and (2) WHO National Influenza Centre (NIC).
Principal Site for Egypt’s First Phase III Mega-Trial for COVID-19 Vaccines
During the global pandemic, VCRC served as the Principal Site for Egypt’s first Phase III Mega-Trial for COVID-19 vaccines. In September 2020, Egypt initiated trials for two Chinese inactivated coronavirus vaccines conducted at VACSERA in cooperation with Chinese and Emirati partners.
Multi-center Efficacy Study of Inactivated Vaccine
1,500+ Participants
Emergency Use Authorization (EUA) & 100% GCP
COVID-19 Vaccine Clinical Trials at VACSERA
Documented Clinical Trials & Collaborative Research Studies
A legacy of successful clinical trials, bioequivalence studies, and epidemiological surveillance conducted with leading partners.
Tetanus Toxoid (TT) vs Reduced Diphtheria (Td) Randomized Controlled Trial
Open-labelled randomized controlled trial in pregnant women evaluating the equivalency of TT and Td in safety and immunogenicity. Conducted by: VACSERA, NODCAR, MOHP Behera Governorate, and U.S. Naval Medical Research Unit No. 3 (NAMRU-3, Cairo, Egypt).
Oral & Inactivated Poliovirus Vaccines (Sequential & Combined Immunization)
Controlled study of reactogenicity and immunogenicity evaluating sequential and combined immunization of infants with oral (OPV) and inactivated (IPV) poliovirus vaccines. By: VACSERA.
Post-Marketing Study on Anti-Snake & Anti-Scorpion Polyvalent Antiserum
Post-marketing clinical study evaluating the safety and clinical efficacy of VACSERA polyvalent anti-snake antiserum & anti-scorpion serum. Conducted at the Poison Control Center, Ain Shams University Hospitals, Egypt.
Expanded Program of Immunization (EPI) Adverse Events Surveillance
Post-marketing surveillance study monitoring adverse events following routine immunization (BCG, OPV, DTPw, HBV, MMR) in children under two years of age in Sharkia Governorate. Conducted by: VACSERA.
Safety & Efficacy of Human Albumin in Cirrhotic Patients (January 2007)
Clinical evaluation of Human Albumin safety and therapeutic efficacy in cirrhotic patients presenting with tense ascites and/or hypoalbuminemia.
Comparative Bioequivalence Study: Human Insulin VACSERA vs Mixtard 30/70
Comparative randomized, single-dose, two-way crossover open-label study to determine the bioequivalence of 30% Short-Acting / 70% Intermediate-Acting NPH Human Insulin (VACSERA SC Injection, Egypt vs Mixtard 30/70 SC Injection, Novo Nordisk, Denmark) in healthy adult volunteers under fasting conditions.
Tuberculin PPD-2 vs PPD-1 Randomized Controlled Study (July 2006)
Randomized controlled study comparing the clinical safety and diagnostic efficacy of proposed PPD-2 against current PPD-1 in Tuberculin 5 Units.
ABEVAC (Bee Venom) Phase IIa Trial in Rheumatoid Arthritis
Open Phase IIa trial evaluating the safety and therapeutic efficacy of ABEVAC (purified bee venom) in patients with rheumatoid arthritis. Performed jointly between EgyVac and the Pharmacological Department at Kasr El-Ainy, alongside clinical studies by Prof. Dr. Darwish El-Hallous (Alexandria).
Apitox for Degenerative Osteoarthritis (Chungbuk National University, Korea)
Phase II randomized active controlled trial evaluating the clinical efficacy of Apitox (purified bee venom solution) in degenerative osteoarthritis patients, in collaboration with the Department of Orthopedic Surgery, College of Medicine, Chungbuk National University, Korea.
Silymarin Multi-Center Phase II/III Clinical Study (MADAUS GmbH, Germany)
Multicenter, double-blind, randomized, placebo-controlled Phase II/III trial evaluating the safety and efficacy of 280 mg and 420 mg Silymarin. Sponsor: MADAUS GmbH, Cologne, Germany.
Monovalent Type 1 (mOPV1) vs Trivalent OPV (WHO POL, Geneva - June 2005)
Comparative randomized double-blind trial evaluating the immunogenicity of Monovalent Type 1 Oral Polio Vaccine (mOPV1) versus Trivalent OPV (tOPV) in Egypt. Sponsor: POL, World Health Organization (WHO), Geneva.
Poliovirus Antibodies Sero-Survey (WHO EMRO - December 2000)
Comprehensive survey of Poliovirus antibodies conducted during the critical final stage of polio eradication in Egypt. Sponsor: POL, WHO EMRO, Cairo.
Registered by the Supreme Council of Research Ethics
The center was officially registered by the Supreme Council of Research Ethics in August 2025 according to the required regulatory guidelines.
CRE Registration Certificate
Supreme Council of Research Ethics — August 2025
IRB Registration Certificate
Institutional Review Board Accreditation
Trusted by Global Health Leaders & Sovereign Bodies
Strong collaborations with international health organizations, universities, and leading pharmaceutical companies.
National Partners & Academic Medical Centers
Ministry of Health and Population (MoHP)
Egyptian Drug Authority (EDA)
Kasr El-Ainy — Cairo University
Ain Shams University HospitalsInternational Partners & Global Organizations
World Health Organization (WHO)
Sinopharm
G42 Healthcare / Sinovac
U.S. NAMRU-3
Chungbuk National University (Korea)
MADAUS GmbH (Germany)VACSERA Clinical Research Center (VCRC)
Affiliated to the Holding Company for Biological Products & Vaccines (VACSERA)
We welcome collaborations with vaccine developers, pharmaceutical sponsors, and global health bodies for GCP-compliant clinical trials and bioequivalence investigations.
Address
51, Wezaret El Zeraa St., Agouza, Giza, Egypt
Telephone & Fax
Tel: 02 37611111 - 1060
Fax: 02 - 37609177
Mobile: 01000702476